CN104968801B - 用于治疗贫血症的生物标志物 - Google Patents

用于治疗贫血症的生物标志物 Download PDF

Info

Publication number
CN104968801B
CN104968801B CN201380067792.8A CN201380067792A CN104968801B CN 104968801 B CN104968801 B CN 104968801B CN 201380067792 A CN201380067792 A CN 201380067792A CN 104968801 B CN104968801 B CN 104968801B
Authority
CN
China
Prior art keywords
gdf11
activity
level
seq
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380067792.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104968801A (zh
Inventor
维多利亚·松
拉杰什·乔普拉
奥利维尔·赫尔米内
伊凡·克鲁兹莫拉
迈克尔·杜赛特
蒂亚戈·特罗瓦蒂马切尔
奥雷利·弗里克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Priority to CN202110622231.6A priority Critical patent/CN113604550A/zh
Publication of CN104968801A publication Critical patent/CN104968801A/zh
Application granted granted Critical
Publication of CN104968801B publication Critical patent/CN104968801B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
CN201380067792.8A 2012-10-24 2013-10-23 用于治疗贫血症的生物标志物 Active CN104968801B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110622231.6A CN113604550A (zh) 2012-10-24 2013-10-23 用于治疗贫血症的生物标志物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261718126P 2012-10-24 2012-10-24
US61/718,126 2012-10-24
PCT/US2013/066350 WO2014066486A2 (en) 2012-10-24 2013-10-23 Biomarker for use in treating anemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110622231.6A Division CN113604550A (zh) 2012-10-24 2013-10-23 用于治疗贫血症的生物标志物

Publications (2)

Publication Number Publication Date
CN104968801A CN104968801A (zh) 2015-10-07
CN104968801B true CN104968801B (zh) 2021-06-15

Family

ID=50545462

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380067792.8A Active CN104968801B (zh) 2012-10-24 2013-10-23 用于治疗贫血症的生物标志物
CN202110622231.6A Pending CN113604550A (zh) 2012-10-24 2013-10-23 用于治疗贫血症的生物标志物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110622231.6A Pending CN113604550A (zh) 2012-10-24 2013-10-23 用于治疗贫血症的生物标志物

Country Status (10)

Country Link
US (2) US20150276766A1 (cg-RX-API-DMAC7.html)
EP (2) EP3608419B1 (cg-RX-API-DMAC7.html)
JP (3) JP6401171B2 (cg-RX-API-DMAC7.html)
CN (2) CN104968801B (cg-RX-API-DMAC7.html)
AU (3) AU2013334659B2 (cg-RX-API-DMAC7.html)
CA (1) CA2889209C (cg-RX-API-DMAC7.html)
ES (2) ES2753811T3 (cg-RX-API-DMAC7.html)
IL (3) IL290653B2 (cg-RX-API-DMAC7.html)
SA (1) SA515360337B1 (cg-RX-API-DMAC7.html)
WO (1) WO2014066486A2 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612041B2 (en) 2005-11-23 2009-11-03 Acceleron Pharma Inc. Isolated activin-binding ActRIIa polypeptide comprising the SEQ ID NO: 7 and uses for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CN101835485B (zh) 2007-02-01 2016-10-26 阿塞勒隆制药公司 活化素-actriia拮抗剂及在治疗或预防乳腺癌中的用途
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
KR101672156B1 (ko) 2007-02-09 2016-11-02 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
WO2009038745A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
US8058229B2 (en) 2008-08-14 2011-11-15 Acceleron Pharma Inc. Method of increasing red blood cell levels or treating anemia in a patient
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
EP2638065A4 (en) 2010-11-08 2014-04-09 Acceleron Pharma Inc ACTRIIA-BINDING SUBSTANCES AND ITS USES
AU2013337677B2 (en) 2012-11-02 2018-06-28 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
EP3131931B1 (en) * 2014-04-18 2020-10-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating sickle-cell disease
BR122023023170A2 (pt) 2014-06-13 2024-02-20 Acceleron Pharma Inc. Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia
MA41052A (fr) * 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
CA2966925C (en) 2014-11-24 2023-08-29 Somalogic, Inc. Nucleic acid compounds for binding growth differentiation factor 11
CN107533040B (zh) * 2014-12-03 2022-03-29 细胞基因公司 激活素-actrii拮抗剂及用于治疗贫血症的用途
SMT202100294T1 (it) 2015-04-22 2021-07-12 Biogen Ma Inc Proteine trappola del liganto acriib ibride innovative per il trattamento di patologie da deperimento muscolare
TN2017000468A1 (en) * 2015-05-13 2019-04-12 Acceleron Pharma Inc TREATMENT OF BETA-THALASSEMIA USING ACTRIl LIGAND TRAPS.
JP2018522579A (ja) * 2015-05-20 2018-08-16 セルジーン コーポレイション アクチビンＩＩ型受容体リガンドトラップを使用するβ−サラセミアのインビトロ細胞培養法
EP3370754A4 (en) 2015-11-04 2019-10-23 Acceleron Pharma Inc. METHOD FOR INCREASING ERYTHROCYTE CONCENTRATION AND TREATMENT OF INEFFICIENT ERYTHROPOIESE
CN105738614B (zh) * 2016-02-23 2017-12-05 山东大学 一种应用流式细胞仪分析评价小鼠骨髓红细胞生成功能的方法
EA201990226A1 (ru) 2016-07-27 2019-08-30 Акселерон Фарма Инк. Способы и композиции для лечения миелофиброза
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
EP4649961A2 (en) 2020-05-15 2025-11-19 Celgene Corporation Methods and compositions for treating anemia using actriib ligand traps and mtor inhibitors
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102655872A (zh) * 2009-08-13 2012-09-05 阿塞勒隆制药公司 Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
ATE305036T1 (de) * 1994-07-08 2005-10-15 Univ Johns Hopkins Med Wachstums-differenzierungsfaktor-11
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
AU8921698A (en) 1997-08-29 1999-03-16 Human Genome Sciences, Inc. Follistatin-3
JP2004526419A (ja) 2000-10-16 2004-09-02 フィロス インク． 抗体模倣物および他の結合タンパク質のためのタンパク質骨格
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
TW200526779A (en) * 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
WO2002088171A2 (en) 2001-04-26 2002-11-07 Avidia Research Institute Combinatorial libraries of monomer domains
JP4429728B2 (ja) * 2002-02-21 2010-03-10 ワイス エルエルシー フォリスタチン（ｆｏｌｌｉｓｔａｔｉｎ）ドメイン含有タンパク質
US20070135336A1 (en) 2003-09-15 2007-06-14 De Kretser David Follistatin isoforms and uses thereof
EP1771470B1 (en) 2004-07-23 2013-06-26 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
US20060234299A1 (en) 2004-11-16 2006-10-19 Avidia Research Institute Protein scaffolds and uses thereof
US8067562B2 (en) * 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
WO2008030367A2 (en) 2006-09-01 2008-03-13 The General Hospital Corporation Selective myostatin inhibitors
EP2468290B1 (en) * 2006-12-18 2015-04-01 Acceleron Pharma, Inc. Activin-ActRII Antagonists for use in treating anemia
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
US20100015144A1 (en) * 2008-06-26 2010-01-21 Acceleron Pharma Inc. Methods for dosing an activin-actriia antagonist and monitoring of treated patients
US8216997B2 (en) * 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
US8058229B2 (en) 2008-08-14 2011-11-15 Acceleron Pharma Inc. Method of increasing red blood cell levels or treating anemia in a patient
HUE035240T2 (hu) * 2009-04-27 2018-05-02 Novartis Ag Készítmények és eljárások az izomerõ növelésére
EP2638065A4 (en) * 2010-11-08 2014-04-09 Acceleron Pharma Inc ACTRIIA-BINDING SUBSTANCES AND ITS USES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102655872A (zh) * 2009-08-13 2012-09-05 阿塞勒隆制药公司 Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平

Also Published As

Publication number Publication date
CN113604550A (zh) 2021-11-05
US20150276766A1 (en) 2015-10-01
IL267663B (en) 2022-09-01
IL290653B2 (en) 2025-05-01
EP2912462A2 (en) 2015-09-02
IL290653A (en) 2022-04-01
EP3608419B1 (en) 2025-03-26
SA515360337B1 (ar) 2019-09-12
JP7146850B2 (ja) 2022-10-04
AU2019204098A1 (en) 2019-07-04
IL238414B (en) 2019-07-31
AU2013334659B2 (en) 2019-07-11
HK1213948A1 (en) 2016-07-15
EP2912462A4 (en) 2016-06-15
ES2753811T3 (es) 2020-04-14
JP2020183389A (ja) 2020-11-12
WO2014066486A2 (en) 2014-05-01
IL267663A (en) 2019-08-29
IL238414A0 (en) 2015-06-30
AU2013334659A1 (en) 2015-05-14
JP2018184428A (ja) 2018-11-22
CA2889209A1 (en) 2014-05-01
AU2019204098B2 (en) 2021-07-22
EP2912462B1 (en) 2019-08-07
IL290653B1 (en) 2025-01-01
US20190049469A1 (en) 2019-02-14
ES3031001T3 (en) 2025-07-03
CN104968801A (zh) 2015-10-07
JP2016500698A (ja) 2016-01-14
JP6401171B2 (ja) 2018-10-03
AU2021236465A1 (en) 2021-10-21
AU2021236465B2 (en) 2024-06-13
WO2014066486A3 (en) 2015-07-16
CA2889209C (en) 2023-08-22
EP3608419A1 (en) 2020-02-12

Similar Documents

Publication Publication Date Title
CN104968801B (zh) 用于治疗贫血症的生物标志物
US20210355191A1 (en) Activin-actrii antagonists and uses for increasing red blood cell levels
EP2303917B1 (en) Antagonists of actriib and uses for increasing red blood cell levels
EP3527219A1 (en) Methods for treating anemia
HK40023193A (en) Biomarker for use in treating anemia
HK1213948B (en) Biomarker for use in treating anemia
HK40012688A (en) Methods for treating anemia
HK40051596A (en) Antagonists of actriib and uses for increasing red blood cell levels
NZ743635B2 (en) Biomarker for use in treating anemia
NZ743635A (en) Biomarker for use in treating anemia
HK1156057B (en) Antagonists of actriib and uses for increasing red blood cell levels
HK1156057A (en) Antagonists of actriib and uses for increasing red blood cell levels

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant